52-Week Mid-term Efficacy of Tildrakizumab in Moderate-to-severe Psoriasis: A Real-life Multicenter Experience
Actas Dermo-Sifiliográficas · 2024
DOI: 10.1016/j.ad.2023.08.019 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Actas Dermo-Sifiliográficas, 2024. Verfasst von F J Melgosa Ramos und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Doctor Peset of Valencia, Valencia, Spain. Electronic address: javimelgo@gmail.com. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Psoriasis, Severity of Illness Index. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Tildrakizumab is an IL-23-inhibitor that has been approved to treat plaque psoriasis. However, few reports have become available on its efficacy profile in the real-world. Our objective was to study the mid-term efficacy of tildrakizumab in patients with moderate-to-severe psoriasis in the Spanish routine clinical practice setting. This was a retrospective multicenter study that included a total of 91 psoriatic patients on tildrakizumab. The mean Psoriasis Area and Severity Index (PASI) was 9.09 (SD, 5.30). The overall tildrakizumab survival rate was 93.47% for a mean treatment exposure of 30.18 weeks (SD, 16.57). No drug discontinuation was associated with drug tolerability, or adverse reactions. Absolute PASI ≤3 was reached by 91.3% and 96.5% of the patients on weeks 28 and 52, respectively. Response was not impacted by weight, age (>65), metabolic syndrome, presence of arthritis, or previous number of biological therapies used. Based on our own experience tildrakizumab is an effective strategy to treat plaque psoriasis and difficult-to-treat-areas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University Hospital Doctor Peset of Valencia, Valencia, Spain. Electronic address: javimelgo@gmail.com.
- Department of Dermatology, University Hospital Doctor Peset of Valencia, Valencia, Spain.
- Department of Dermatology, Hospital Marina Alta, Vila-Joyosa, Alicante, Spain.
- Department of Dermatology, Hospital de la Vega Baja, Orihuela, Alicante, Spain.
- Department of Dermatology, General University Hospital of Alicante, Alicante, Spain.
- Department of Dermatology, University Hospital Virgen de los Lirios, Alcoy, Alicante, Spain.
Zitieren
APA
Melgosa Ramos, F. J., Mateu Puchades, A., Matáix-Díaz, J., Schneller-Pavelescu, L., Belinchón-Romero, I., & Santos Alarcón, S. (2024). 52-Week Mid-term Efficacy of Tildrakizumab in Moderate-to-severe Psoriasis: A Real-life Multicenter Experience. Actas Dermo-Sifiliográficas. https://doi.org/10.1016/j.ad.2023.08.019
Vancouver
Melgosa Ramos FJ, Mateu Puchades A, Matáix-Díaz J, Schneller-Pavelescu L, Belinchón-Romero I, Santos Alarcón S. 52-Week Mid-term Efficacy of Tildrakizumab in Moderate-to-severe Psoriasis: A Real-life Multicenter Experience. Actas Dermo-Sifiliográficas. 2024. doi:10.1016/j.ad.2023.08.019
BibTeX
@article{MelgosaRamos2024,
author = {Melgosa Ramos, F J and Mateu Puchades, A and Matáix-Díaz, J and Schneller-Pavelescu, L and Belinchón-Romero, I and Santos Alarcón, S},
title = {52-Week Mid-term Efficacy of Tildrakizumab in Moderate-to-severe Psoriasis: A Real-life Multicenter Experience},
journal = {Actas Dermo-Sifiliográficas},
year = {2024},
doi = {10.1016/j.ad.2023.08.019}
}
EUVIMED